title: Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
authors.affiliation: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
authors.forename: Veena
authors.initials: V
authors.lastname: Rao
authors.affiliation: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
authors.forename: Eric
authors.initials: E
authors.lastname: Schneider
authors.affiliation: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina2Department of Pathology, Duke University Medical Center, Durham, North Carolina.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Proia
authors.affiliation: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
authors.forename: Sharon
authors.initials: S
authors.lastname: Fekrat
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D053626:Atovaquone / Q000627:therapeutic use; D002825:Chorioretinitis / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005260:Female; D016266:Food Parasitology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D014122:Toxoplasma / Q000302:isolation & purification; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology
chemical_list: D000890:Anti-Infective Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D053626:Atovaquone